These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
207 related articles for article (PubMed ID: 2186629)
1. Susceptibility to nucleoside analogues of zidovudine-resistant isolates of human immunodeficiency virus. Richman DD Am J Med; 1990 May; 88(5B):8S-10S. PubMed ID: 2186629 [TBL] [Abstract][Full Text] [Related]
2. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Tisdale M; Kemp SD; Parry NR; Larder BA Proc Natl Acad Sci U S A; 1993 Jun; 90(12):5653-6. PubMed ID: 7685907 [TBL] [Abstract][Full Text] [Related]
3. Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2',3'-dideoxyinosine or AZT plus 2',3'-dideoxycytidine combination therapy. The protocol 34,225-02 Collaborative Group. Larder BA; Kohli A; Bloor S; Kemp SD; Harrigan PR; Schooley RT; Lange JM; Pennington KN; St Clair MH J Virol; 1996 Sep; 70(9):5922-9. PubMed ID: 8709213 [TBL] [Abstract][Full Text] [Related]
4. AZT resistance in isolates of HIV. Richman DD Immunodefic Rev; 1991; 2(4):315-8. PubMed ID: 2059436 [TBL] [Abstract][Full Text] [Related]
8. Response of Ethiopian human immunodeficiency virus type 1 isolates to antiviral compounds. Wondimu Z; Sönnerborg A; Ayehunie S; Britton S; Strannegård O Antiviral Res; 1992 Oct; 19(4):353-9. PubMed ID: 1281393 [TBL] [Abstract][Full Text] [Related]
9. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Larder BA; Darby G; Richman DD Science; 1989 Mar; 243(4899):1731-4. PubMed ID: 2467383 [TBL] [Abstract][Full Text] [Related]
10. Reverse transcriptase sequence of paired isolates of cerebrospinal fluid and blood from patients infected with human immunodeficiency virus type 1 during zidovudine treatment. Di Stefano M; Sabri F; Leitner T; Svennerholm B; Hagberg L; Norkrans G; Chiodi F J Clin Microbiol; 1995 Feb; 33(2):352-5. PubMed ID: 7536214 [TBL] [Abstract][Full Text] [Related]
11. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. St Clair MH; Martin JL; Tudor-Williams G; Bach MC; Vavro CL; King DM; Kellam P; Kemp SD; Larder BA Science; 1991 Sep; 253(5027):1557-9. PubMed ID: 1716788 [TBL] [Abstract][Full Text] [Related]
12. Human immunodeficiency virus inhibition is prolonged by 3'-azido-3'-deoxythymidine alternating with 2',3'-dideoxycytidine compared with 3'-azido-3'-deoxythymidine alone. Spector SA; Ripley D; Hsia K Antimicrob Agents Chemother; 1989 Jun; 33(6):920-3. PubMed ID: 2548440 [TBL] [Abstract][Full Text] [Related]
13. In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine. Gao Q; Gu ZX; Parniak MA; Li XG; Wainberg MA J Virol; 1992 Jan; 66(1):12-9. PubMed ID: 1727474 [TBL] [Abstract][Full Text] [Related]
14. Sequence analysis of reverse transcriptase genes of zidovudine (AZT)-resistant and -sensitive human immunodeficiency virus type 1 strains. Sheehy N; Desselberger U J Gen Virol; 1993 Feb; 74 ( Pt 2)():223-8. PubMed ID: 7679140 [TBL] [Abstract][Full Text] [Related]
15. Resistance to AZT and ddC during long-term combination therapy in patients with advanced infection with human immunodeficiency virus. Richman DD; Meng TC; Spector SA; Fischl MA; Resnick L; Lai S J Acquir Immune Defic Syndr (1988); 1994 Feb; 7(2):135-8. PubMed ID: 7905522 [TBL] [Abstract][Full Text] [Related]
16. Anti-HIV type 1 activity of 3'-fluoro-3'-deoxythymidine for several different multidrug-resistant mutants. Kim EY; Vrang L; Oberg B; Merigan TC AIDS Res Hum Retroviruses; 2001 Mar; 17(5):401-7. PubMed ID: 11282008 [TBL] [Abstract][Full Text] [Related]
17. Biological comparison of wild-type and zidovudine-resistant isolates of human immunodeficiency virus type 1 from the same subjects: susceptibility and resistance to other drugs. Rooke R; Parniak MA; Tremblay M; Soudeyns H; Li XG; Gao Q; Yao XJ; Wainberg MA Antimicrob Agents Chemother; 1991 May; 35(5):988-91. PubMed ID: 1649576 [TBL] [Abstract][Full Text] [Related]
18. Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine. García-Lerma JG; MacInnes H; Bennett D; Weinstock H; Heneine W J Virol; 2004 Jul; 78(14):7545-52. PubMed ID: 15220429 [TBL] [Abstract][Full Text] [Related]
19. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC]. Taylor DL; Ahmed PS; Tyms AS; Wood LJ; Kelly LA; Chambers P; Clarke J; Bedard J; Bowlin TL; Rando RF Antivir Chem Chemother; 2000 Jul; 11(4):291-301. PubMed ID: 10950391 [TBL] [Abstract][Full Text] [Related]
20. Implication of the tRNA initiation step for human immunodeficiency virus type 1 reverse transcriptase in the mechanism of 3'-azido-3'-deoxythymidine (AZT) resistance. Vaccaro JA; Anderson KS Biochemistry; 1998 Oct; 37(40):14189-94. PubMed ID: 9760256 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]